Current status of endocrine therapy for prostate cancer in Japan - Analysis of primary androgen deprivation therapy on the basis of data vollected by J-CaP

Japanese Journal of Clinical Oncology

Volumn 37, Issue 10, 2007, Pages 775-781

  Hinotsu, Shiro ^a   Akaza, Hideyuki ^a   Usami, Michiyuki ^b   Ogawa, Osamu ^c   Kagawa, Susumu ^d   Kitamura, Tadaichi ^e   Tsukamoto, Taiji ^f   Naito, Seiji ^g   Namiki, Mikio ^h   Hirao, Yoshihiko ⁱ   Murai, Masaru ^j   Yamanaka, Hidetoshi ^k  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h KANAZAWA UNIVERSITY   (Japan)

ⁱ NARA MEDICAL UNIVERSITY   (Japan)

^j KEIO UNIVERSITY   (Japan)

^k Kurosawa Hospital   (Japan)

more..

Author keywords

J CaP; Primary androgen deprivation therapy; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CASTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROGNOSIS; PROSTATE CANCER; SHORT COURSE THERAPY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIETHYLSTILBESTROL; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM STAGING; NITRILES; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 36249012526     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym098     Document Type: Article

References (13)

1. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 2006;97:243-7.
2. Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T, et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 2004;34:329-36.
3. SAS Institute. JMP Statistics and Graphic Guide. Cary, NC: SAS Institute, 2000.
4. UICC. TNM Classification of the Malignant Tumors, 5th edn, edited by Sobin LH, Wittekind Ch. New York: Wiley-Liss, 1997.
5. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderrick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
6. Shahinian VB, Kuo Y, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;103:1615-24.
7. Japanese Urological Association, The Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Prostate Cancer, 3rd edn. Tokyo: Kanehara Syuppan, 2001.
8. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-9.
9. Japanese Urological Association. Clinical Guideline for Prostate Cancer 2006. Tokyo: Kanehara Syuppan, 2006.
10. Akaza H, Homma Y, Okada K, Yokoyama M, Usami M, Hirao Y, et al. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: Results of the 5-year follow-up. BJU Int 2003;91:33-6.
11. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12:46-61.
12. Kawakami J, Cowan JE, Elken EP, Latini DM, DuChance J, Carroll PRfor the CaPSURE Investigators. Androgen-deprivation therapy as primary treatment for localized prostate cancer (Data from Cancer of the prostate strategic urologic research endeavor (CaPSURE)). Cancer 2006;106:1708-14.
13. Shabinian VB, Kuo Y, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: Role of urologist. J Natl Cancer Inst 2006;98:839-45.